Immunotherapeutics are drugs that work by modulating the immune system to fight disease. The Company currently is evaluating its lead immunotherapeutic, Oncophage, in six clinical trials for the treatment of four different cancers, and it expects to start its first pivotal clinical trial by mid-2000. The Company also is developing immunotherapeutics to treat infectious diseases such as genital herpes, and autoimmune disorders such as diabetes and multiple sclerosis. Based upon its scientific and drug development skills, technology platform and strategic expertise, the Company intends to become a leader in drug discovery, development and commercialization.
Revenues reflect product sales attributable to the acquisition of Aquila.
Market Guide offers more in-depth Company Research , Stock Screening , and Hottest Stocks and Industries on over 10,000 U.S. Equities. All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Event data provided by StreetEvents . Data and information is provided for informational purposes only, and is not intended for trading purposes.